509 related articles for article (PubMed ID: 20599299)
1. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study.
El-Azab AS; Al-Omar MA; Abdel-Aziz AA; Abdel-Aziz NI; el-Sayed MA; Aleisa AM; Sayed-Ahmed MM; Abdel-Hamide SG
Eur J Med Chem; 2010 Sep; 45(9):4188-98. PubMed ID: 20599299
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase.
Abouzid K; Shouman S
Bioorg Med Chem; 2008 Aug; 16(16):7543-51. PubMed ID: 18678492
[TBL] [Abstract][Full Text] [Related]
3. New substituted 4-arylaminoquinazolines as potent inhibitors of breast tumor cell lines: in vitro and docking experiments.
de Oliveira AN; Bocca CC; Carvalho JE; Ruiz AL; Silva TP; Rittner R; Hoehr NF
Eur J Med Chem; 2010 Sep; 45(9):4339-42. PubMed ID: 20627376
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential anti-cancer agents.
Alafeefy AM; Ashour AE
J Enzyme Inhib Med Chem; 2012 Aug; 27(4):541-5. PubMed ID: 21851213
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of chrysin long-chain derivatives as potential anticancer agents.
Lv PC; Wang KR; Li QS; Chen J; Sun J; Zhu HL
Bioorg Med Chem; 2010 Feb; 18(3):1117-23. PubMed ID: 20056425
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives.
Chandregowda V; Kush AK; Chandrasekara Reddy G
Eur J Med Chem; 2009 Jul; 44(7):3046-55. PubMed ID: 18771819
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity.
Li HQ; Li DD; Lu X; Xu YY; Zhu HL
Bioorg Med Chem; 2012 Jan; 20(1):317-23. PubMed ID: 22112541
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel 2,4'-bis substituted diphenylamines as anticancer agents and potential epidermal growth factor receptor tyrosine kinase inhibitors.
Abou-Seri SM
Eur J Med Chem; 2010 Sep; 45(9):4113-21. PubMed ID: 20580136
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.
Rao GW; Xu GJ; Wang J; Jiang XL; Li HB
ChemMedChem; 2013 Jun; 8(6):928-33. PubMed ID: 23640754
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
Lv PC; Zhou CF; Chen J; Liu PG; Wang KR; Mao WJ; Li HQ; Yang Y; Xiong J; Zhu HL
Bioorg Med Chem; 2010 Jan; 18(1):314-9. PubMed ID: 19914835
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.
Hou J; Wan S; Wang G; Zhang T; Li Z; Tian Y; Yu Y; Wu X; Zhang J
Eur J Med Chem; 2016 Aug; 118():276-89. PubMed ID: 27132165
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antiproliferative activity of indolizine derivatives incorporating a cyclopropylcarbonyl group against Hep-G2 cancer cell line.
Shen YM; Lv PC; Chen W; Liu PG; Zhang MZ; Zhu HL
Eur J Med Chem; 2010 Jul; 45(7):3184-90. PubMed ID: 20304535
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
[TBL] [Abstract][Full Text] [Related]
16. Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects.
Antonello A; Tarozzi A; Morroni F; Cavalli A; Rosini M; Hrelia P; Bolognesi ML; Melchiorre C
J Med Chem; 2006 Nov; 49(23):6642-5. PubMed ID: 17154492
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
[TBL] [Abstract][Full Text] [Related]
18. Benzothiazoles: search for anticancer agents.
Noolvi MN; Patel HM; Kaur M
Eur J Med Chem; 2012 Aug; 54():447-62. PubMed ID: 22703845
[TBL] [Abstract][Full Text] [Related]
19. Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold.
Chilin A; Conconi MT; Marzaro G; Guiotto A; Urbani L; Tonus F; Parnigotto P
J Med Chem; 2010 Feb; 53(4):1862-6. PubMed ID: 20095624
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antitumor evaluation of novel 5-substituted-4-hydroxy-8-nitroquinazolines as EGFR signaling-targeted inhibitors.
Jin Y; Li HY; Lin LP; Tan J; Ding J; Luo X; Long YQ
Bioorg Med Chem; 2005 Oct; 13(19):5613-22. PubMed ID: 15993078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
